Thursday, April 23, 2026
ISSN 2765-8767
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us

The Future of Healthcare Consumerism

Summary

In this episode of the Daily Remedy Podcast, the host delves into the evolving landscape of healthcare consumerism as we approach 2026. The discussion highlights how patients are increasingly becoming empowered consumers, driven by rising healthcare costs and the need for transparency and predictability in their care. The host emphasizes that this shift is not merely about convenience but reflects a deeper transformation in how patients engage with healthcare, akin to consumer behavior in other industries. The emergence of technologies, particularly AI, is reshaping the patient-provider dynamic, enabling patients to take a more active role in their healthcare decisions.

Takeaways

Patients are becoming empowered consumers in healthcare.
Healthcare consumerism is maturing into a demand for transparency and trust.
Technology is enabling patients to take on a more active role in their healthcare decisions.
Patients want predictable pricing and upfront cost estimates.
The shift towards patient empowerment is reshaping the healthcare landscape.

 

Daily Remedy

Daily Remedy

Dr. Jay K Joshi serves as the editor-in-chief of Daily Remedy. He is a serial entrepreneur and sought after thought-leader for matters related to healthcare innovation and medical jurisprudence. He has published articles on a variety of healthcare topics in both peer-reviewed journals and trade publications. His legal writings include amicus curiae briefs prepared for prominent federal healthcare cases.

Leave a Reply

Your email address will not be published. Required fields are marked *

Videos

Policy Shift in Peptide Regulation

FDA Evaluation of Certain Bulk Drug Substances in Compounding: Clinical Interpretation

FDA Evaluation of Certain Bulk Drug Substances in Compounding: Clinical Interpretation

Clinicians increasingly encounter patients using or requesting peptide-based therapies sourced through compounding pharmacies. The U.S. Food and Drug Administration has identified a subset of bulk drug substances, including certain peptides, that may present significant safety risks when used in compounded formulations. The clinical question is whether these regulatory signals reflect meaningful patient-level risk and how they should influence prescribing behavior. This matters because compounded peptides often sit outside traditional approval pathways, creating uncertainty around quality, dosing consistency, and safety. Understanding...

Read more

Join Our Newsletter!